Mateon Therapeutics Stock Price, News & Analysis (OTCMKTS:MATN)

$0.16 0.00 (0.00 %)
(As of 01/16/2018 02:56 AM ET)
Previous Close$0.16
Today's Range$0.15 - $0.18
52-Week Range$0.09 - $0.89
Volume137,517 shs
Average Volume142,844 shs
Market Capitalization$4.24 million
P/E Ratio-0.29
Dividend YieldN/A
Beta1.5

About Mateon Therapeutics (OTCMKTS:MATN)

Mateon Therapeutics logoMateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MATN
CUSIPN/A
Phone+1-650-6357000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.42%
Quick Ratio2.42%

Price-To-Earnings

Trailing P/E Ratio-0.285535714285714
Forward P/E Ratio-0.31
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book0.34

Profitability

Trailing EPS($0.56)
Net Income$-13,650,000.00
Net MarginsN/A
Return on Equity-210.82%
Return on Assets-175.67%

Miscellaneous

Employees16
Outstanding Shares26,550,000

Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) released its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter. View Mateon Therapeutics' Earnings History.

Where is Mateon Therapeutics' stock going? Where will Mateon Therapeutics' stock price be in 2018?

4 equities research analysts have issued 1 year price objectives for Mateon Therapeutics' stock. Their forecasts range from $1.00 to $2.00. On average, they anticipate Mateon Therapeutics' share price to reach $1.75 in the next twelve months. View Analyst Ratings for Mateon Therapeutics.

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:

  • William D. Schwieterman M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
  • Matthew M. Loar CPA, Chief Financial Officer, Principal Accounting Officer (Age 51)
  • David Chaplin Ph.D., Chief Scientific Officer, Director (Age 59)
  • Simon C. Pedder Ph.D., Director (Age 56)
  • Donald R. Reynolds, Independent Director (Age 54)
  • Bobby W. Sandage Jr., Ph.D., Independent Director (Age 63)

How do I buy Mateon Therapeutics stock?

Shares of Mateon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of Mateon Therapeutics stock can currently be purchased for approximately $0.16.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $4.24 million. The biopharmaceutical company earns $-13,650,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Mateon Therapeutics employs 16 workers across the globe.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 701 Gateway Blvd Ste 210, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-6357000 or via email at [email protected]


MarketBeat Community Rating for Mateon Therapeutics (MATN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mateon Therapeutics (OTCMKTS:MATN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.75$1.75$2.00$2.00
Price Target Upside: 651.07% upside651.07% upside455.56% upside344.44% upside

Mateon Therapeutics (OTCMKTS:MATN) Consensus Price Target History

Price Target History for Mateon Therapeutics (OTCMKTS:MATN)

Mateon Therapeutics (OTCMKTS:MATN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/22/2017HC WainwrightReiterated RatingBuy$1.00View Rating Details
8/1/2017Maxim GroupReiterated RatingHoldView Rating Details
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$2.00View Rating Details
3/13/2017Rodman & RenshawReiterated RatingBuy -> Buy$2.00View Rating Details
1/29/2016S&P Equity ResearchLower Price Target$0.64 -> $0.58View Rating Details
(Data available from 1/16/2016 forward)

Earnings

Mateon Therapeutics (OTCMKTS:MATN) Earnings History and Estimates Chart

Earnings by Quarter for Mateon Therapeutics (OTCMKTS:MATN)

Mateon Therapeutics (OTCMKTS MATN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.13)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.12)($0.15)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.13)($0.15)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.13)($0.13)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.15)($0.12)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.14)ViewN/AView Earnings Details
5/9/2016Q116($0.19)($0.13)ViewN/AView Earnings Details
3/28/2016Q4 2015($0.14)($0.15)ViewN/AView Earnings Details
11/10/2015Q3($0.13)($0.14)ViewN/AView Earnings Details
8/4/2015Q215($0.10)($0.13)ViewN/AView Earnings Details
4/30/2015Q115($0.13)($0.13)ViewN/AView Earnings Details
4/14/2015($0.13)($0.11)ViewN/AView Earnings Details
3/17/2015Q414($0.17)($0.11)ViewN/AView Earnings Details
11/12/2014Q3($0.23)($0.17)ViewListenView Earnings Details
8/5/2014Q2 2014($0.13)($0.23)ViewN/AView Earnings Details
5/6/2014Q1 2014($0.19)($0.29)ViewN/AView Earnings Details
3/18/2014Q412($4.67)ViewN/AView Earnings Details
11/12/2013Q3($1.88)ViewListenView Earnings Details
8/6/2013Q2 2013($0.74)ViewN/AView Earnings Details
5/6/2013Q1 2013($0.97)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.92)ViewN/AView Earnings Details
11/8/2012Q312($0.13)ViewN/AView Earnings Details
8/8/2012Q2 2012($1.64)ViewN/AView Earnings Details
5/9/2012Q1 2012($1.44)ViewN/AView Earnings Details
3/13/2012Q4 2011($1.39)ViewN/AView Earnings Details
11/9/2011Q3 2011($3.12)($2.03)ViewN/AView Earnings Details
8/10/2011Q2 2011($5.52)($3.87)ViewN/AView Earnings Details
5/12/2011Q1 2011($6.60)($1.58)ViewN/AView Earnings Details
11/4/2010Q3 2010($24.01)($41.78)ViewN/AView Earnings Details
8/12/2010Q2 2010($21.61)($17.29)ViewN/AView Earnings Details
5/11/2010Q1 2010($26.41)($39.14)ViewN/AView Earnings Details
2/25/2010Q4 2009($31.21)($28.57)ViewN/AView Earnings Details
11/9/2009Q3 2009($28.81)($68.43)ViewN/AView Earnings Details
7/30/2009Q2 2009($33.61)($26.41)ViewN/AView Earnings Details
5/11/2009Q1 2009($33.61)($29.05)ViewN/AView Earnings Details
3/19/2009Q4 2008($38.42)($32.89)ViewN/AView Earnings Details
11/5/2008Q3 2008($48.02)($59.30)ViewN/AView Earnings Details
8/4/2008Q2 2008($52.82)($59.78)ViewN/AView Earnings Details
5/5/2008Q1 2008($50.42)($46.58)ViewN/AView Earnings Details
2/28/2008Q4 2007($48.02)($49.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mateon Therapeutics (OTCMKTS:MATN) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.51 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Mateon Therapeutics (OTCMKTS:MATN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mateon Therapeutics (OTCMKTS MATN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Insider Trades by Quarter for Mateon Therapeutics (OTCMKTS:MATN)

Mateon Therapeutics (OTCMKTS MATN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2016Donald Rogers ReynoldsDirectorBuy30,000$0.35$10,500.0012,700View SEC Filing  
6/28/2013Peter LangeckerCEOBuy3,000$2.75$8,250.00View SEC Filing  
6/25/2013Peter LangeckerCEOBuy2,000$2.79$5,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mateon Therapeutics (OTCMKTS MATN) News Headlines

Source:
DateHeadline
Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ... - GlobeNewswire (press release)Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 5:25 PM
Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint InhibitorsMateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors
finance.yahoo.com - January 8 at 9:53 AM
Mateon Therapeutics to Present at the 2018 Biotech Showcase - GlobeNewswire (press release)Mateon Therapeutics to Present at the 2018 Biotech Showcase - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:06 PM
Mateon Therapeutics to Present at the 2018 Biotech ShowcaseMateon Therapeutics to Present at the 2018 Biotech Showcase
finance.yahoo.com - January 3 at 8:41 AM
Mateon Therapeutics (MATN) vs. Mirati Therapeutics (MRTX) Head to Head SurveyMateon Therapeutics (MATN) vs. Mirati Therapeutics (MRTX) Head to Head Survey
www.americanbankingnews.com - December 30 at 3:16 PM
Analyzing Grifols SA, Barcelona (GRFS) and Mateon Therapeutics (MATN)Analyzing Grifols SA, Barcelona (GRFS) and Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 28 at 11:40 AM
Mateon Therapeutics (MATN) versus Trillium Therapeutics (TRIL) Critical SurveyMateon Therapeutics (MATN) versus Trillium Therapeutics (TRIL) Critical Survey
www.americanbankingnews.com - December 25 at 3:26 PM
Financial Comparison: Jazz Pharmaceuticals (JAZZ) vs. Mateon Therapeutics (MATN)Financial Comparison: Jazz Pharmaceuticals (JAZZ) vs. Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 22 at 9:20 PM
Analyzing Trillium Therapeutics (TRIL) & Mateon Therapeutics (MATN)Analyzing Trillium Therapeutics (TRIL) & Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 7 at 7:28 PM
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor - GlobeNewswire (press release)Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor - GlobeNewswire (press release)
globenewswire.com - December 5 at 5:15 PM
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint InhibitorMateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
finance.yahoo.com - December 5 at 10:12 AM
Critical Contrast: Mateon Therapeutics (MATN) and XOMA (XOMA)Critical Contrast: Mateon Therapeutics (MATN) and XOMA (XOMA)
www.americanbankingnews.com - November 30 at 9:30 AM
Financial Contrast: Mateon Therapeutics (MATN) versus Anavex Life Sciences Corp. (AVXL)Financial Contrast: Mateon Therapeutics (MATN) versus Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - November 23 at 3:14 PM
HC Wainwright Reiterates Buy Rating for Mateon Therapeutics, Inc. (MATN)HC Wainwright Reiterates Buy Rating for Mateon Therapeutics, Inc. (MATN)
www.americanbankingnews.com - November 22 at 4:26 PM
Mateon Therapeutics, Inc. (MATN) Posts Quarterly  Earnings ResultsMateon Therapeutics, Inc. (MATN) Posts Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 2:01 PM
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:13 AM
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsMateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:13 AM

SEC Filings

Mateon Therapeutics (OTCMKTS:MATN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mateon Therapeutics (OTCMKTS:MATN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mateon Therapeutics (OTCMKTS MATN) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.